Company intelligence / Profile preview

Shining Biotechnology

Shanghai, Shanghai, Chinaprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

Shining Biotechnology specializes in innovative cell therapies and cancer vaccines aimed at extending patient survival, reducing treatment pain, improving quality of life, and providing better options for critically ill patients. It collaborates closely with Japan’s leading immuno-oncology institute to advance next-generation immune therapies. No published clinical results or approved products were found as of the latest update.

Therapeutic areas: Oncology
Modalities: Cell therapyVaccine
Industry: Biotech

Partnerships

The Institute of Medical Oncology (TIMO), Japan

Beyond the preview

Go deeper on Shining Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shining Biotechnology.

Explore the full profile